Citigroup: Opinions on drug pricing highlight government support signal, innovative pharmaceutical companies such as Hengrui expected to benefit.

The General Office of the State Council issued the "Several Opinions on Improving the Drug Pricing Mechanism." Citigroup has stated that this is the most important guiding document issued by the central government on drug pricing since 2015 and sees it as an important signal of the government's clear commitment to supporting domestic pharmaceutical and biopharmaceutical industries with global competitiveness. The policy goal is to allow the market to play a greater decisive role in drug price formation, with a focus on innovative drug companies and biopharmaceutical companies such as CSPC Pharmaceutical Group, Chi-Med, Innovent Biologics, and other multinational companies benefiting from it.